Lung Clinical Trial
Official title:
A Randomized Trial Comparing a Ventilatory Strategy To Prevent Atelectasis Versus a Lateral Decubitus Strategy During Robotic Bronchoscopy (VESPA vs. LADS Trial)
To learn if LADS is better than VESPA at preventing atelectasis during a robotic bronchoscopy.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | September 14, 2032 |
Est. primary completion date | September 14, 2032 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Adult patients (= 18 years old) undergoing diagnostic robotic bronchoscopy for a lung nodule suspicious for malignancy bronchoscopy under general anesthesia. 2. Lung nodules should be up to 3 cm in diameter and located in right or left bronchial segments B2, B6, B9, and B10. Greater than 50% of the volume of the lesion needs to be below a horizontal line traced at the most anterior edge of the corresponding vertebral body. 3. Chest CT performed < 4 weeks prior to bronchoscopy. 4. Voluntary informed consent to participate in the study. Exclusion Criteria: 1. Patients with prior lung consolidation, interstitial changes or lung masses (> 3 cm in diameter) as seen on most recent CT 2. Lesions outside of the designated lung areas defined as inclusion criteria. 3. Known pregnancy 4. Vulnerable population 5. Ascites 6. Known diaphragmatic paralysis 7. Smokers or ex-smokers with known or suspected severe air-trapping defined as residual volume > 150% of predicted 8. History of primary or secondary spontaneous pneumothorax 9. Lung bullae > 5 cm 10. Patients with mediastinal or hilar adenopathy with high suspicion for malignancy in whom lymph node sampling is indicated and should occur prior to robotic bronchoscopy of the peripheral lesion. 11. Patient with active COVID pneumonia. |
Country | Name | City | State |
---|---|---|---|
United States | M D Anderson Cancer Center | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
M.D. Anderson Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 | through study completion; an average of 1 year. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00026689 -
Evaluation for NCI Radiation Oncology Branch Clinical Research Protocols
|
||
Recruiting |
NCT05055739 -
Comparative Study Between Sternal Closure With Sternalock® Blue Versus Steel Wire Submitted To Bilateral Anterior Transsternal Thoracotomy (Clamshell) For Bilateral Lung Transplant
|
N/A | |
Not yet recruiting |
NCT04616820 -
Endocan Blood Level in Pulmonary Circulation
|
||
Recruiting |
NCT02201446 -
The Role of Circulating Soluble CD74 in Acute Lung Injury
|
N/A | |
Completed |
NCT02833246 -
Using a Patient-Centered mHealth Intervention to Improve Adherence to Oral Anticancer Medications
|
N/A | |
Recruiting |
NCT06115395 -
Non-invasive Ventilation Assisted Fiber-optic Bronchoscopy
|
N/A | |
Withdrawn |
NCT00588263 -
Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer
|
N/A | |
Completed |
NCT05268263 -
Feasibility of AI-based Classification of Normal, Wheeze and Crackle Sounds From Stethoscope in Clinical Settings
|
N/A | |
Active, not recruiting |
NCT02849041 -
Screening of Tobacco-induced Cancers by Low-dose CT-scanner and Identification of Circulating Tumor Cells
|
N/A | |
Recruiting |
NCT05050370 -
A Brief SMART Exercise Instant Messaging Support Intervention - a Pilot Study
|
N/A | |
Completed |
NCT00484016 -
Drug Delivery and Toxicities of Adjuvant Chemotherapy in Resected NCSLC
|
N/A | |
Completed |
NCT00972205 -
Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors
|
N/A | |
Completed |
NCT02535013 -
Intraoperative Lung Ultrasound in Pediatric Patients
|
N/A |